Engineering heparin-azithromycin microparticulate nasal gels for the dual prophylaxis and therapy of COVID-19 and bacterial respiratory infections

Abstract

The SARS-CoV-2 pandemic highlighted the need for effective prophylactic and local treatment strategies against respiratory viruses. The nasal cavity is a critical site for pathogen entry and colonization, and is therefore a critical target for targeted interventions. SARS-CoV-2, as a plethora of other virus, primarily spreads via respiratory droplets infecting nasal epithelial cells. Concurrently, bacteria such as Streptococcus pneumoniae and Pseudomonas aeruginosa, frequently colonize the nasal cavity, causing co-infections and serving as reservoirs for further respiratory tract involvement. This study presents a nasal gel that combines heparin and azithromycin (AZM) microparticles to combat both viral and bacterial infections in the nasal cavity. The formulation exhibits a favorable safety profile with minimal haemolytic toxicity (HC50 > 82 × 10⁷ μg/mL), potent activity against P. aeruginosa and S. pneumoniae at low concentrations (MIC of 15.6 µg/mL and 7.8 µg/mL, respectively), and effective antiviral properties (IC50 of 0.062 µg/mL for Pseudovirus inhibition). These multifaceted properties position the formulation as a promising candidate for a convenient, dual-action therapy in respiratory infection management, offering potentially both treatment and prophylaxis.

Rights

This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Downloadable citations

Identifiers

Repository URI

https://strathprints.strath.ac.uk/94807/